Key result
Mitochondria-targeted therapies may benefit diabetic cardiomyopathy by addressing hyperglycemic stress-driven mitochondrial dysfunction.
This review highlights the central role of mitochondrial dysfunction in diabetic cardiomyopathy and outlines potential mitochondria-targeted therapeutic strategies.
No takes yet. Share an insight, caveat, or question.
Mitochondrial pathways in diabetic cardiomyopathy merit targeted study; leaves open whether chaperone modulation alters clinical outcomes.
Zhi et al. (2023) conducted a review in Diabetic cardiomyopathy. Mitochondrial dysfunction, driven by hyperglycemic stress, plays a central role in diabetic cardiomyopathy, suggesting that mitochondria-targeted therapies may offer potential clinical benefits.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: